TRCT
BGLC icon

Tower Research Capital (TRC)’s BioNexus Gene Lab BGLC Stock Holding History

Tower Research Capital (TRC)’s Portfolio BGLC Stock Details BGLC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-583
Closed -$3.09K – 5854
2023
Q4 		$3.09K Buy
+583
New +$3.31K ﹤0.01% 5126

Other funds holding BGLC

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s BGLC Position: Q1 2024 in Review

Tower Research Capital (TRC) sold out of BioNexus Gene Lab (BGLC) in Q1 2024, closing a stake of 583 shares — an estimated $3.09K sold.

Tower Research Capital (TRC) first reported a position in BGLC in Q4 2023 and held it in 1 quarter. The position peaked at $3.09K in Q4 2023. 4 funds tracked by Wall St. Rank hold BGLC as of Q1 2024.

  • Tower Research Capital (TRC) reported no remaining BioNexus Gene Lab position as of Q1 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 583 BioNexus Gene Lab shares in Q1 2024, an estimated $3.09K.
  • Tower Research Capital (TRC) first reported a position in BioNexus Gene Lab in Q4 2023 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s BioNexus Gene Lab position peaked at $3.09K in Q4 2023.
  • 4 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2024, filed 15 May 2024.